www.ijarp.com ISSN 2456-9992 Page: 01-14

International Journal Advanced Research Publications

Review Article

Volume: 02
Issue: 04

PHARMACOTHERAPEUTIC ADVANCES AND EMERGING TREATMENT STRATEGIES IN RETT SYNDROME: A COMPREHENSIVE REVIEW

[1]Messala Gowthami ,[2]Yeligeti Navya* ,[3] Rohit Kumar Panda , [4] Thalasani Soumya, [5]Pandu Range reddy.

[1]Associate Professor , Clinical Pharmacy Practice Department , Malla Reddy College of Pharmacy , Dhulapally ,Secunderabad , Telangana-500100.

[2,3,4,5] Pharm-D 4th year, Malla Reddy College of Pharmacy, Dhulapally, Secunderabad , Telangana-500100.

Article Received: 21 February 2026, Article Revised: 12 March 2026, Published on: 01 April 2026

***Corresponding Author: Yeligeti Navya**

Associate Professor , Clinical Pharmacy Practice Department , Malla Reddy College of Pharmacy , Dhulapally ,Secunderabad , Telangana-500100.

DOI: https://doi-doi.org/101555/ijarp.1228

ABSTRACT:

Rett syndrome (RTT) is a rare X-linked neurodevelopmental disorder. It is marked by a progressive loss of motor and cognitive abilities, repetitive hand movements, autonomic dysfunction, and epilepsy. This disorder mainly affects females and is often caused by mutations in the methyl-CpG binding protein 2 (MECP2) gene. Although the disorder was first described in 1966, major progress in molecular genetics over the last two decades has greatly improved understanding of its biological effects and treatment targets. Historically, treatment focused on managing symptoms with anticonvulsants, muscle relaxants, and behavioral therapies. Recently, advancements in molecular pharmacology have led to targeted therapies that aim to correct the underlying neurobiological issues. Notably, trofinetide, an insulin-like growth factor-1 analog, is now the first disease-specific therapy approved for Rett syndrome. Additionally, ongoing research is exploring gene therapy, RNA editing, neurotrophic factor modulation, and new small-molecule drugs. This review covers the genetic basis, molecular mechanisms, clinical features, current pharmacological management, and emerging therapies for Rett syndrome. It highlights recent clinical trials and research that could influence future treatment strategies for this complex disorder.

KEYWORDS: Rett syndrome, Mecp2 gene , mutation , neurodevelopmental disorder , trofinetide.

1.INTRODUCTION:

Rett syndrome (RTT) is a severe neurodevelopmental disorder that leads to progressive neurological impairment, intellectual disability, and distinctive motor problems. It predominantly affects females and has an estimated global prevalence of 1 in 10,000 to 15,000 female births. RTT is one of the most common genetic causes of intellectual disability in females and significantly contributes to neurological issues in children. The condition usually appears after a period of normal early development. Infants generally develop well in the first 6 to 18 months but then experience rapid neurodevelopmental regression.During this regression phase, children lose previously gained speech and purposeful hand skills and develop typical repetitive hand movements like wringing or clapping. The discovery of MECP2 gene mutations in 1999 was a crucial breakthrough in understanding the molecular basis of Rett syndrome. The MECP2 protein is vital for neuronal development, regulating gene transcription and aiding synaptic maturation. Mutations in this gene disrupt neuronal balance, leading to numerous neurodevelopmental issues. Despite significant gains in understanding the molecular mechanisms behind Rett syndrome, treatment options remain limited. Current therapies mainly focus on symptom management, but recent advances in molecular pharmacology and neurogenetics have led to new pharmacological and gene-based interventions aimed at altering disease progression. This review provides a detailed overview of Rett syndrome, focusing on developments in pharmacotherapy, emerging treatments, and progress in translational research.

FIG 1.1

2. EPIDEMIOLOGY:

Rett syndrome is considered rare but has a significant clinical impact due to its serious neurological effects. Key epidemiological features include: - Prevalence: 1 in 10,000 to 15,000 female births - Accounts for about 2 to 3% of profound intellectual disability cases in females - Occurs worldwide in different ethnic groups The condition rarely affects males because it is X-linked. Male infants with MECP2 mutations often develop severe neonatal encephalopathy and may not survive infancy.

Genetic Basis : Most cases of Rett syndrome are caused by mutations in the MECP2 gene, found on chromosome Xq28. The MECP2 gene encodes a protein that regulates gene expression in neurons by binding to methylated DNA.

Types of MECP2 mutations include:

- Missense mutations
- Nonsense mutations
- Frameshift mutations
- Insertions or deletions
- Splice-site mutations.

About eight common mutation hotspots account for nearly 70% of RTT cases. The severity of clinical manifestations often correlates with the type of MECP2 mutation and the patterns of X-chromosome inactivation.

3.PATHOPHYSIOLOGY:

Neurological symptoms in Rett syndrome mainly stem from disrupted regulation of neuronal genes due to MECP2 dysfunction.

- Role of MECP2 in Neural Development MECP2 is highly expressed in mature neurons, playing several critical roles, such as: - Regulating gene transcription - Remodeling chromatin - Aiding neuronal maturation - Supporting synaptic plasticity Loss or dysfunction of MECP2 leads to widespread issues in gene transcription, affecting multiple neuronal signaling pathways.
- Synaptic Dysfunction One major pathological mechanism in Rett syndrome is impaired synaptic connectivity. Studies have shown: - Reduced dendritic spine density - Impaired synaptic plasticity - Abnormal activity in neuronal networks These changes significantly contribute to cognitive and behavioral problems in affected individuals.
- Neurotransmitter Imbalance Several neurotransmitter systems are impacted in Rett syndrome: - **Glutamatergic system:** Excess glutamate signaling leads to

excitotoxicity and damage to neurons. - **GABAergic system:** Reduced inhibitory signaling disrupts stability in neuronal networks. - **Dopaminergic and serotonergic pathways:** Changes in these systems contribute to motor dysfunction, mood issues, and autonomic problems.

- Neurotrophic Factor Dysregulation MECP2 helps regulate the expression of brain-derived neurotrophic factor (BDNF), which is essential for neuronal survival and synaptic development. Lower BDNF levels result in: - Impaired synaptic maturation - Reduced neuronal connectivity - Altered neural plasticity .
- Neuroinflammation and Oxidative Stress Recent studies indicate that neuroinflammation may play a role in the progression of Rett syndrome. Activated microglia release pro-inflammatory cytokines, such as: - Interleukin-1β - Tumor necrosis factor-α These inflammatory markers may worsen neuronal dysfunction and degeneration.

4. SYMPTOMS

Babies with Rett syndrome are born after an uncomplicated pregnancy and delivery. Most infants with Rett syndrome grow and behave as expected for the first six months.

The most changes generally occur at 12 to 18 months of age, over a period of weeks or months.

The main signs and symptoms include:

- Slowed growth Brain growth slows after birth.
- Loss of movement & coordination abilities.
- Loss of communication abilities.
- Unusual hand movements**.**

Other signs and symptoms can include:

- Unusual eye movements.
- Breathing problems.
- Irritability and crying.
- Other unusual behaviors.
- Intellectual disabilities.
- Seizures.
- Sideways curvature of the spine (scoliosis).
- Irregular heartbeat.

- Sleep disturbances
- Other symptoms. A variety of other symptoms can occur such as:
- a decreased response to pain
- small hands and feet which are cold
- problems with chewing and swallowing
- problems with bowel function
- And teeth grinding.

FIG 4.1

5.CLINICAL FEATURES:

Staging Rett syndrome generally progresses through four clinical stages.

Stage I – Early Onset Stage - Age: 6 to 18 months - Symptoms include: - Subtle developmental delays - Reduced eye contact - Diminished interest in surroundings .

Stage II – Rapid Regression Stage - Age: 1 to 4 years - Key features: - Loss of speech - Loss of purposeful hand use - Repetitive hand movements - Irritability and sleep issues .

Stage III – Plateau Stage - Age: 2 to 10 years - Characteristics: - Stabilization of symptoms - Ongoing motor deficits - Seizures and irregular breathing .

Stage IV – Late Motor Deterioration - Age: adolescence and onward - Features include: - Progressive motor impairment - Scoliosis - Muscle weakness - Reduced mobility.



FIG 5.1

6.DIAGNOSIS

- Diagnosing Rett syndrome mainly relies on clinical assessment and genetic testing.

Diagnostic Criteria Updated guidelines stress the need for:

- Regression of acquired skills

- Loss of hand function

- Repetitive hand movements

- Abnormalities in walking.

Genetic testing confirming an MECP2 mutation supports the diagnosis.

- Biomarkers Promising biomarkers being studied include:

- MECP2 protein expression

- Plasma BDNF levels

- Metabolic markers- Indicators from neuroimaging . These biomarkers may help in early diagnosis and monitoring therapy.

7.PHARMACOLOGICAL TREATMENT :

Current treatment aims to manage symptoms rather than cure the disorder.

Antiepileptic Therapy - Seizures affect about 60 to 80% of patients.

Common medications include:

- Valproic acid
- Lamotrigine
- Levetiracetam
- Topiramate

Drug	MOA	DOSE	ADR's
Valproic acid	Increases GABA concentration in brain by inhibiting degradation. Blocks voltage-gated sodium channels. Reduces neuronal hyperexcitability.	Initial: 10–15 mg/kg/day Maintenance: 20–60 mg/kg/day in divided doses	Nausea, vomiting, Weight gain,Tremor, Hepatotoxicity & Thrombocytopenia
Lamotrigine	Blocks voltage-gated sodium channels. Inhibits release of excitatory neurotransmitters.	Initial: 0.6 mg/kg/day Maintenance: 5–15 mg/kg/day (divided doses)	Skin rash Stevens–Johnson syndrome (rare but serious),Headache, Dizziness ,Nausea
Levetiracetam	Binds to synaptic vesicle protein SV2A, modulating neurotransmitter release and reducing neuronal excitability.	Initial: 10 mg/kg/day Maintenance: 20–60 mg/kg/day in two divided doses	Dizziness ,Fatigue & Irritability or behavioral changes
Topiramate	Blocks voltage-dependent sodium channels & Enhances GABA activity. Antagonizes AMPA/kainate glutamate receptors	Initial: 1–3 mg/kg/day Maintenance: 5–9 mg/kg/day in divided doses	Weight loss, Cognitive slowing , Kidney stones &Fatigue

Trofinetide (Daybue) in Rett syndrome

It's the First FDA-approved drug specifically for the treatment of Rett syndrome.

Helps to improve core symptoms such as communication, behavior, and motor function.

- MOA: Trofinetide is a synthetic analogue of glypromate, a neurotrophic peptide derived from insulin-like growth factor-1 (IGF-1).

It helps reduce neuroinflammation, improve synaptic function and support neuronal signaling which is impaired in Rett syndrome.

Dose:

Administered orally twice daily (every 12 hours).

Dose is based on body weight:

Body weight	Dose(BD)
9-12 kg	5 g
12-20 kg	6 g
20-35 kg	8 g
35-50 kg	10 g
>50 kg	12 g

- ADRs:

Diarrhea (most common) , Vomiting , Decreased appetite ,Weight loss & Fatigue.

- Clinical Note:

Trofinetide improves overall functioning and quality of life, but it does not cure Rett syndrome; supportive therapy and seizure management are still required.

Treatment is tailored to the type of seizure and patient response.

- Management of Movement Disorders

Motor dysfunction and muscle stiffness are treated with:

- Baclofen

- Benzodiazepines

- Gabapentin - Physical therapy often accompanies these medications.

- Treatment of Behavioral and Mood Disorders

Behavioral issues may be managed with:

- Selective serotonin reuptake inhibitors

- Atypical antipsychotics :These medications can help with anxiety, irritability, and mood swings.

- Management of Autonomic Dysfunction Breathing issues and autonomic disturbances are common. Pharmacological options include:

- Beta-blockers & Serotonin modulators ,However, evidence for these treatments is limited.

FIG 7.1

GENE THERAPY & STEM CELL THERAPY

Gene therapy is one of the most promising strategies for Rett syndrome.

Methods include:

- Viral vector-mediated gene replacement
- CRISPR-based gene editing
- RNA-based therapies Animal studies indicate that restoring MECP2 expression can reverse neurological symptoms. However, there are challenges related to ensuring safe gene dosage and long-term safety.

Stem Cell Therapy

Stem cell transplantation is being researched as a potential regenerative option.

Possible mechanisms include:

- Neuronal regeneration
- Restoring synaptic connectivity
- Modulating neuroinflammation .

While preclinical results are encouraging, clinical evidence is still limited.

8. CHALLENGES IN PHARMACOTHERAPY :

Development Developing drugs for Rett syndrome faces several challenges:

- Rare disease population
- Genetic diversity
- Difficulty measuring clinical outcomes
- Blood-brain barrier limitations
- Long clinical trial timelines .

These hurdles underscore the need for innovative research and international collaboration.

9. FUTURE PERSPECTIVES

Future therapeutic strategies may involve:

- Precision medicine
- Early genetic screening
- Combination therapies that target multiple pathways
- Better biomarkers for monitoring treatment .

Advances in genomics, neuropharmacology, and biotechnology are expected to change how Rett syndrome is managed.

FIG 9.1

10. CONCLUSION :

Rett syndrome is a complex neurodevelopmental disorder mainly caused by mutations in the MECP2 gene. While current treatments largely focus on symptom management, recent

advances in molecular pharmacology have introduced promising strategies that may modify the disease. The approval of trofinetide marks a notable achievement in Rett syndrome therapy. Ongoing research into gene therapy, neurotrophic modulation, and new pharmacological agents could further enhance treatment outcomes and quality of life for those affected.

11. REFERENCES:

1. Neul JL, Kaufmann WE, GlazeDG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68:944-950.
2. Ip JPK, Mellios N, Sur M. Rett syndrome: insights into genetic, molecular and circuit mechanisms. Nat Rev Neurosci. 2018;19:368-382.
3. Banerjee A, Miller MT, Li K, et al. Toward a better understanding of Rett syndrome. Nat Rev Neurosci. 2019;20:437-453.
4. Katz DM, Bird A, Coenraads M, et al. Rett syndrome: crossing the threshold to clinical translation. Trends Neurosci. 2016;39:100-113.
5. O'Leary HM, Kaufmann WE, Barnes KV, et al. Placebo-controlled trial of trofinetide in Rett syndrome. Lancet Neurol. 2023;22:411-422.
6. Percy AK. Rett syndrome: exploring the autism link. Arch Neurol. 2011;68:985-989.
7. Lyst MJ, Bird A. Rett syndrome: a complex disorder with simple roots. Nat Rev Genet. 2015;16:261-275.
8. Glaze DG, Percy AK, Skinner S, et al. Epilepsy and the natural history of Rett syndrome. Neurology. 2010;74:909-912.
9. Guy J, Gan J, Selfridge J, et al. Reversal of neurological defects in a mouse model of Rett syndrome. Science. 2007;315:1143-1147.
10. Kaufmann WE, Stallworth JL, Everman DB, Skinner SA. Neurobiologically-based treatments in Rett syndrome. Clin Neuropharmacol. 2016;39:1-8.
11. Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2 encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23(2):185-188.
12. Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron. 2007;56(3):422-437.
13. Guy J, Cheval H, Selfridge J, Bird A. The role of MeCP2 in the brain. Annu Rev Cell Dev Biol. 2011;27:631-652.
14. Na ES, Nelson ED, Adachi M, et al. Mechanisms of disease in Rett syndrome. Brain Dev. 2012;34(10):814-823.

15. Percy AK. Rett syndrome: clinical correlates of the molecular genetics. Brain Dev. 2011;33(7):536-541.
16. Neul JL, Fang P, Barrish J, et al. Specific mutations in methyl-CpG binding protein 2 confer different severity in Rett syndrome. Neurology. 2008;70(16):1313-1321.
17. Zoghbi HY. Postnatal neurodevelopmental disorders: meeting at the synapse? Science. 2003;302(5646):826-830.
18. Samaco RC, Neul JL. Complexities of Rett syndrome and MeCP2. J Neurosci. 2011;31(22):7951-7959.
19. Lyst MJ, Bird A. Rett syndrome: a complex disorder with simple roots. Nat Rev Genet. 2015;16(5):261-275.
20. Katz DM, Berger-Sweeney JE, Eubanks JH, et al. Preclinical research in Rett syndrome: setting the foundation for translational success. Dis Model Mech. 2012;5(6):733-745.
21. Leonard H, Cobb S, Downs J. Clinical and biological progress over 50 years in Rett syndrome. Nat Rev Neurol. 2017;13(1):37-51.
22. Benfenati F, Sala C. Rett syndrome: from molecular pathogenesis to therapeutic perspectives. Neurosci Biobehav Rev. 2016;71:190-205.
23. Blue ME, Naidu S, Johnston MV. Altered synaptic transmission in Rett syndrome. Brain Dev. 2015;37(7):677-685.
24. Shepherd GM, Katz DM. Synaptic microcircuit dysfunction in genetic models of Rett syndrome. Nat Neurosci. 2011;14(3):307-313.
25. Banerjee A, Miller MT, Li K, et al. Toward a better understanding of Rett syndrome. Nat Rev Neurosci. 2019;20(7):437-453.
26. Tang X, Gudsnuk K, Kuo SH, et al. MeCP2 regulates activity-dependent transcriptional responses in neurons. Neuron. 2016;79(1):35-48.
27. Skene PJ, Illingworth RS, Webb S, et al. Neuronal MeCP2 is expressed at near histone-octamer levels. Science. 2010;329(5998):1667-1670.
28. Krishnaraj R, Ho G, Christodoulou J. Rett syndrome: a clinical update. Mol Syndromol. 2017;8(3):125-136.
29. Sandweiss AJ, Brandt VL, Zoghbi HY. Advances in understanding of Rett syndrome and MECP2 duplication syndrome. Nat Rev Neurol. 2020;16(3):147-161.
30. Ausió J, Martinez de Paz A, Esteller M. MeCP2: the long trip from a chromatin protein to neurological disorders. Trends Mol Med. 2014;20(9):487-498.

31. Kaufmann WE, Stallworth JL, Everman DB, Skinner SA. Neurobiologically-based treatments in Rett syndrome: opportunities and challenges. Clin Neuropharmacol. 2016;39(1):1-8.
32. Glaze DG, Percy AK, Skinner S, et al. Epilepsy and the natural history of Rett syndrome. Neurology. 2010;74(11):909-912.
33. Tarquinio DC, Hou W, Berg A, et al. Longitudinal course of epilepsy in Rett syndrome. Epilepsia. 2017;58(7):1083-1092.
34. Downs J, Leonard H. Quantifying the benefits of physical therapy in Rett syndrome. Dev Med Child Neurol. 2016;58(4):321-326.
35. Katz DM, Bird A, Coenraads M, et al. Rett syndrome: crossing the threshold to clinical translation. Trends Neurosci. 2016;39(2):100-113.
36. O'Leary HM, Kaufmann WE, Barnes KV, et al. Placebo-controlled trial of trofinetide in Rett syndrome. Lancet Neurol. 2023;22(5):411-422.
37. Glaze DG, Neul JL, Percy AK, et al. A double-blind, randomized, placebo-controlled trial of trofinetide in Rett syndrome. Pediatr Neurol. 2019;96:60-66.
38. Khwaja OS, Ho E, Barnes KV, et al. Safety and efficacy of mecasermin in Rett syndrome. Ann Neurol. 2014;75(6):818-828.
39. Djukic A, Holtzer R, Shinnar S, et al. Pharmacologic treatment of breathing abnormalities in Rett syndrome. Pediatr Neurol. 2016;58:63-70.
40. Garg SK, Lioy DT, Cheval H, et al. Systemic delivery of MeCP2 rescues behavioral and cellular deficits in Rett syndrome models. Nat Neurosci. 2013;16(9):1151-1159.
41. Gadalla KK, Bailey ME, Cobb SR. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy. Biochem J. 2011;439(1):1-14.
42. Robinson L, Guy J, McKay L, et al. Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome. Brain. 2012;135(9):2699-2710.
43. Tillotson R, Bird A. The molecular basis of MeCP2 function in the brain. J Mol Biol. 2020;432(6):1602-1623.
44. Rodrigues DC, Kim DS, Yang G, et al. MECP2 is post-transcriptionally regulated during human neurodevelopment. Hum Mol Genet. 2016;25(23):4933-4945.
45. Bedogni F, Hodge RD, Nelson BR, et al. Early transcriptional changes in Rett syndrome. Hum Mol Genet. 2016;25(14):2899-2914.
46. Kron M, Howell CJ, Adams IT, et al. Brain activity mapping in Rett syndrome models. J Neurosci. 2012;32(24):8557-8567.

47. Guy J, Hendrich B, Holmes M, et al. A mouse model for Rett syndrome. Nat Genet. 2001;27(3):322-326.
48. Sandweiss AJ, Brandt VL, Zoghbi HY. Advances in therapeutic development for Rett syndrome. Nat Rev Drug Discov. 2020;19(11):747-765.
49. Pozzo-Miller L, Pati S, Percy AK. Rett syndrome: pathophysiology and treatment strategies. Curr Opin Pediatr. 2015;27(6):728-735.
50. Cuddapah VA, Pillai RB, Shekar KV, et al. Mitochondrial dysfunction in Rett syndrome. J Neurochem. 2014;128(1):32-41.